

# CONTENTS

---

<b>NOTE TO THE READER.....</b>	<b>1</b>
<b>LIST OF PARTICIPANTS .....</b>	<b>3</b>
<b>PREAMBLE.....</b>	<b>9</b>
<b>A. GENERAL PRINCIPLES AND PROCEDURES .....</b>	<b>9</b>
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review .....	11
4. Data for the <i>Monographs</i> .....	12
5. Meeting participants .....	12
6. Working procedures.....	13
<b>B. SCIENTIFIC REVIEW AND EVALUATION .....</b>	<b>14</b>
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary .....	26
6. Evaluation and rationale.....	27
References.....	31
<b>GENERAL REMARKS .....</b>	<b>33</b>
<b>MALATHION .....</b>	<b>36</b>
1. Exposure Data.....	36
1.1 Identification of the agent .....	36
1.2 Production and use.....	37
1.3 Measurement and analysis.....	39
1.4 Occurrence and exposure.....	39

2. Studies of Cancer in Humans.....	46
2.1 Scope of available epidemiological studies.....	46
2.2 Summary of frequently cited epidemiological studies.....	51
2.3 Cohort studies on malathion.....	61
2.4 Case-control studies on lympho-haematopoietic cancers and malathion.....	72
2.5 Case-control studies on other cancers.....	81
2.6 Meta-analysis.....	86
3. Cancer in Experimental Animals.....	86
3.1 Mouse.....	86
3.2 Rat.....	91
4. Mechanistic and Other Relevant Data.....	100
4.1 Absorption, distribution, metabolism, and excretion.....	100
4.2 Mechanisms of carcinogenesis.....	106
4.3 Data relevant to comparisons across agents and end-points.....	127
4.4 Susceptibility.....	133
4.5 Other adverse effects.....	135
5. Summary of Data Reported.....	137
5.1 Exposure data.....	137
5.2 Human carcinogenicity data.....	138
5.3 Animal carcinogenicity data.....	140
5.4 Mechanistic and other relevant data.....	140
6. Evaluation.....	142
6.1 Cancer in humans.....	142
6.2 Cancer in experimental animals.....	142
6.3 Overall evaluation.....	142
6.4 Rationale.....	142
References.....	143
<b>PARATHION.....</b>	<b>160</b>
1. Exposure Data.....	160
1.1 Identification of the agent.....	160
1.2 Production and use.....	161
1.3 Measurement and analysis.....	162
1.4 Occurrence and exposure.....	162
2. Cancer in Humans.....	164
2.1 Introduction.....	164
2.2 Cohort studies.....	164
2.3 Case-control studies.....	171
2.4 Meta-analyses.....	173
3. Cancer in Experimental Animals.....	173
3.1 Mouse.....	173
3.2 Rat.....	175
4. Mechanistic and Other Relevant Data.....	182
4.1 Toxicokinetic data.....	182
4.2 Mechanisms of carcinogenesis.....	188
4.3 Data relevant to comparisons across agents and end-points.....	200

---

4.4 Susceptibility .....	207
4.5 Other adverse effects .....	208
5. Summary of Data Reported .....	209
5.1 Exposure data.....	209
5.2 Human carcinogenicity data.....	209
5.3 Animal carcinogenicity data.....	210
5.4 Mechanistic and other relevant data.....	211
6. Evaluation.....	212
6.1 Cancer in humans.....	212
6.2 Cancer in experimental animals.....	212
6.3 Overall evaluation .....	212
References.....	212
<b>DIAZINON.....</b>	<b>223</b>
1. Exposure Data.....	223
1.1 Identification of the agent .....	223
1.2 Production and use.....	224
1.3 Measurement and analysis.....	225
1.4 Occurrence and exposure.....	225
2. Cancer in Humans .....	229
2.1 Summary of frequently cited epidemiological studies.....	229
2.2 Cohort studies .....	229
2.3 Case-control studies on lympho-haematopoietic cancers .....	249
2.4 Case-control studies on other cancers.....	259
2.5 Meta-analysis.....	267
3. Cancer in Experimental Animals .....	267
3.1 Mouse.....	267
3.2 Rat .....	268
4. Mechanistic and Other Relevant Data .....	269
4.1 Toxicokinetic data .....	269
4.2 Mechanisms of carcinogenesis.....	276
4.3 Data relevant to comparisons across agents and end-points .....	293
4.4 Susceptibility .....	300
4.5 Other adverse effects .....	300
5. Summary of Data Reported .....	301
5.1 Exposure data.....	301
5.2 Human carcinogenicity data.....	302
5.3 Animal carcinogenicity data.....	304
5.4 Mechanistic and other relevant data.....	305
6. Evaluation.....	306
6.1 Cancer in humans.....	306
6.2 Cancer in experimental animals.....	306
6.3 Overall evaluation .....	306
6.4 Rationale .....	306
References.....	306

<b>GLYPHOSATE</b> .....	<b>321</b>
1. Exposure Data.....	321
1.1 Identification of the agent.....	321
1.2 Production and use.....	322
1.3 Measurement and analysis.....	324
1.4 Occurrence and exposure.....	325
2. Cancer in Humans.....	331
2.0 General discussion of epidemiological studies.....	331
2.1 Cohort studies.....	331
2.2 Case–control studies on non-Hodgkin lymphoma, multiple myeloma, and leukaemia.....	336
2.3 Case–control studies on other cancer sites.....	349
2.4 Meta-analyses.....	350
3. Cancer in Experimental Animals.....	350
3.1 Mouse.....	350
3.2 Rat.....	355
4. Mechanistic and Other Relevant Data.....	361
4.1 Toxicokinetic data.....	361
4.2 Mechanisms of carcinogenesis.....	365
4.3 Data relevant to comparisons across agents and end-points.....	393
4.4 Cancer susceptibility data.....	393
4.5 Other adverse effects.....	393
5. Summary of Data Reported.....	394
5.1 Exposure data.....	394
5.2 Human carcinogenicity data.....	395
5.3 Animal carcinogenicity data.....	396
5.4 Other relevant data.....	396
6. Evaluation.....	398
6.1 Cancer in humans.....	398
6.2 Cancer in experimental animals.....	398
6.3 Overall evaluation.....	398
6.4 Rationale.....	398
References.....	399
 <b>TETRACHLORVINPHOS</b> .....	 <b>413</b>
1. Exposure Data.....	413
1.1 Identification of the agent.....	413
1.2 Production and use.....	414
1.3 Measurement and analysis.....	415
1.4 Occurrence and exposure.....	416
2. Cancer in Humans.....	417
2.1 Summary of frequently cited epidemiological studies.....	417
2.2 Cohort studies.....	417
2.3 Case–control studies on lympho-haematopoietic cancers.....	418
3. Cancer in Experimental Animals.....	421
3.1 Mouse.....	421
3.2 Rat.....	427

4. Mechanistic and Other Relevant Data .....	430
4.1 Toxicokinetic data .....	430
4.2 Mechanisms of carcinogenesis.....	433
4.3 Data relevant to comparisons across agents and end-points .....	438
4.4 Susceptibility .....	442
4.5 Other adverse effects .....	442
5. Summary of data reported.....	443
5.1 Exposure data.....	443
5.2 Human carcinogenicity data.....	443
5.3 Animal carcinogenicity data.....	444
5.4 Mechanistic and other relevant data.....	444
6. Evaluation.....	445
6.1 Cancer in humans.....	445
6.2 Cancer in experimental animals.....	445
6.3 Overall evaluation .....	445
References.....	445
<b>LIST OF ABBREVIATIONS.....</b>	<b>450</b>
<b>ANNEX 1. SUPPLEMENTAL MATERIAL.....</b>	<b>452</b>

